Unity Biotechnology, Inc.
UBX
$0.977
-$0.0067-0.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 15.46M | 16.41M | 21.79M | 22.14M | 22.74M |
| Gross Profit | -15.46M | -16.41M | -21.79M | -22.14M | -22.74M |
| SG&A Expenses | 15.70M | 15.46M | 15.42M | 15.95M | 17.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.76M | 28.47M | 28.26M | 30.63M | 35.50M |
| Operating Income | -27.76M | -28.47M | -28.26M | -30.63M | -35.50M |
| Income Before Tax | -27.50M | -25.99M | -21.89M | -30.19M | -40.37M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.50 | -25.99 | -21.89 | -30.19 | -40.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.50M | -25.99M | -21.89M | -30.19M | -40.37M |
| EBIT | -27.76M | -28.47M | -28.26M | -30.63M | -35.50M |
| EBITDA | -26.94M | -27.60M | -27.36M | -29.65M | -34.42M |
| EPS Basic | -1.63 | -1.54 | -1.32 | -1.95 | -2.70 |
| Normalized Basic EPS | -0.92 | -0.86 | -0.80 | -0.95 | -1.43 |
| EPS Diluted | -1.63 | -1.54 | -1.32 | -1.95 | -2.70 |
| Normalized Diluted EPS | -0.92 | -0.86 | -0.80 | -0.95 | -1.43 |
| Average Basic Shares Outstanding | 67.39M | 67.31M | 66.19M | 63.94M | 61.55M |
| Average Diluted Shares Outstanding | 67.39M | 67.31M | 66.19M | 63.94M | 61.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |